Technology

Drug/Biotech Stock Q2 Earnings on Aug 5: REGN, MRNA & More

Per the Earnings Trends report of Jul 29, 35.2% of the companies in the Medical sector, constituting nearly 52% of the sector’s market capitalization, have already reported earnings. While 84.2% beat earnings estimates, 89.5% beat the same for sales. Earnings are up 5.6% year over year while revenues are up 5.5%. Overall, second-quarter earnings for the Medical sector, comprising pharma/biotech and medical device companies, are expected to be down 3% while sales are expected to be up 1.9%.

Several large biotech and drugmakers reported their results last week. Pfizer, Lilly, Sanofi and Merck reported mixed results, beating estimates for earnings while missing the same for sales. Pfizer and Merck raised their guidance for both earnings and sales for 2020. Lilly raised its earnings expectations for the year while keeping its sales guidance intact. While Glaxo and Gilead missed estimates on both counts, AstraZeneca and Vertex beat estimates for both earnings and sales.

Let’s analyze five drug/biotech companies that are set to report second-quarter 2020 results on Aug 5.

Regeneron Pharmaceuticals REGN

Regeneron has an impressive track record. It surpassed earnings estimates by 10.08%, on average, in the last four quarters.

Regeneron Pharmaceuticals, Inc. Price and EPS Surprise

Regeneron Pharmaceuticals, Inc. Price and EPS Surprise

Regeneron Pharmaceuticals, Inc. price-eps-surprise | Regeneron Pharmaceuticals, Inc. Quote

Regeneron has an Earnings ESP of -3.68% and a Zacks Rank #4 (Sell).

Per our proven model, stocks with the combination of a positive earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) have a good chance of delivering an earnings beat. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.

The Zacks Consensus Estimate for earnings stands at $6.23 per share.

Sales of Regeneron’s key drug, Eylea, are likely to be have been strong in the second quarter. Apart from Eylea, investors will be focusing on Dupixent’s (sales are recorded by Sanofi) performance and label expansion, which has been the primary growth driver in the last few quarters.

Moderna, Inc. MRNA

This biotech’s earnings beat the Zacks Consensus Estimate in each of the last four quarters with the average surprise being 8.92%.

Moderna, Inc. Price and EPS Surprise

Moderna, Inc. Price and EPS Surprise

Moderna, Inc. price-eps-surprise | Moderna, Inc. Quote

This #2 Ranked company has an Earnings ESP of -0.93%. The Zacks Consensus Estimate stands at a loss of 36 cents per share. You can see the complete list of today’s Zacks #1 Rank stocks here

The company has been actively engaged in developing its coronavirus vaccine — mRNA-1273. It is one of the leading players in this field with phase III study initiated recently. Investors will likely focus on updates on mRNA-1273 on the second-quarter conference call.

Sarepta Therapeutics SRPT

The company’s earnings beat estimates only once in the last four quarters while missing in the other three, resulting in four-quarter average negative surprise of 63.97%.

Sarepta Therapeutics, Inc. Price and EPS Surprise

Sarepta Therapeutics, Inc. Price and EPS Surprise

Sarepta Therapeutics, Inc. price-eps-surprise | Sarepta Therapeutics, Inc. Quote

Sarepta has an Earnings ESP of -2.53% and a Zacks Rank #4.

The Zacks Consensus Estimate for stands at a loss of $1.73 per share.

Product revenues are expected to have risen year over year driven by Sarepta’s Duchenne muscular dystrophy (DMD) drug, Exondys 51. The FDA granted accelerated approval to Sarepta’s second DMD drug, Vyondys 53, in December 2019. However, patient initiation on the drug is expected to have been affected due to COVID-19 in the second quarter.

ACADIA Pharmaceuticals ACAD

The company has a good track record, delivering an earnings beat in three of the trailing four quarters while missing in one. The four-quarter earnings surprise was 7.72%, on average

ACADIA Pharmaceuticals Inc. Price and EPS Surprise

ACADIA Pharmaceuticals Inc. Price and EPS Surprise

ACADIA Pharmaceuticals Inc. price-eps-surprise | ACADIA Pharmaceuticals Inc. Quote

ACADIA has an Earnings ESP of +4.23% and a Zacks Rank #3, indicating a likely earnings beat.

The Zacks Consensus Estimate stands at a loss of 44 cents per share.

Investors will be keen to know if COVID-19 had any impact on sales of ACADIA’s sole marketed drug, Nuplazid, when it reports results.

Horizon Therapeutics Public Limited Company HZNP

The company’s earnings beat estimates in each of the past four quarters with the average surprise being 43.99%.

Horizon Therapeutics Public Limited Company Price and EPS Surprise

Horizon Therapeutics Public Limited Company Price and EPS Surprise

Horizon Therapeutics Public Limited Company price-eps-surprise | Horizon Therapeutics Public Limited Company Quote

Horizon Therapeutics has an Earnings ESP of 0.00% and a Zacks Rank #1 The Zacks Consensus Estimate for earnings stands at 39 cents.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.

A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Click to get this free report

Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report

Moderna, Inc. (MRNA): Free Stock Analysis Report

Sarepta Therapeutics, Inc. (SRPT): Free Stock Analysis Report

Horizon Therapeutics Public Limited Company (HZNP): Free Stock Analysis Report

ACADIA Pharmaceuticals Inc. (ACAD): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Technology Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More